Design Therapeutics Inc - ESG Rating & Company Profile powered by AI
The ESG rating for Design Therapeutics Inc indicates the company's transparency towards the UN Sustainable Development Goals. If you work at Design Therapeutics Inc and you wish to licence your ESG rating, please contact us. The analysis of Design Therapeutics Inc was assembled by All Street Sevva using advanced AI.
Design Therapeutics Inc in the Pharmaceuticals industry gained a UN SDG ESG Transparency Score of 3.4; made up of an environmental score of 3.2, social score of 1.6 and governance score of 5.3.
3.4
Low ImpactEnvironmental
Social
Governance
Peer Group Comparison
| Rank | Company | SDG Transparency Score ⓘ | Performance |
|---|---|---|---|
| 1 | Novartis AG | 9.2 | High |
| 2 | Daiichi Sankyo Co Ltd | 8.9 | High |
| ... | ... | ... | |
| 1617 | VistaGen Therapeutics Inc | 3.5 | Medium |
| 1617 | Yumanity Therapeutics Inc | 3.5 | Medium |
| 1659 | Design Therapeutics Inc | 3.4 | Medium |
| 1659 | Acceleron Pharma Inc | 3.4 | Medium |
| 1659 | Annexin Pharmaceuticals AB (publ) | 3.4 | Medium |
| ... | ... | ... | |
| 2749 | Xynomic Pharmaceuticals Holdings Inc | 0.0 | Low |
| 2749 | Zyden Gentec Ltd | 0.0 | Low |
| ... | ... | ... |
Frequently Asked Questions
Does Design Therapeutics Inc have an accelerator or VC vehicle to help deliver innovation?
Sign up for free to unlockDoes Design Therapeutics Inc disclose current and historical energy intensity?
Sign up for free to unlockDoes Design Therapeutics Inc report the average age of the workforce?
Sign up for free to unlockDoes Design Therapeutics Inc reference operational or capital allocation in relation to climate change?
Sign up for free to unlockDoes Design Therapeutics Inc disclose its ethnicity pay gap?
Sign up for free to unlockDoes Design Therapeutics Inc disclose cybersecurity risks?
Sign up for free to unlockDoes Design Therapeutics Inc offer flexible work?
Sign up for free to unlockDoes Design Therapeutics Inc have a long term incentive (LTI) executive compensation plan based on a measure of return on capital?
Sign up for free to unlockDoes Design Therapeutics Inc disclose the number of employees in R&D functions?
Sign up for free to unlockDoes Design Therapeutics Inc conduct supply chain audits?
Sign up for free to unlockDoes Design Therapeutics Inc disclose incidents of non-compliance in relation to the health and safety impacts of products and services?
Sign up for free to unlockIs there a statment that there is no plan to expand their cement production? (for example: 'We have no current plans to add additional cement making capacity')
Sign up for free to unlockDoes Design Therapeutics Inc conduct 360 degree staff reviews?
Sign up for free to unlockDoes Design Therapeutics Inc disclose the individual responsible for D&I?
Sign up for free to unlockDoes Design Therapeutics Inc disclose current and historical air emissions?
Sign up for free to unlockIs there a statment that there is no plan to expand their coal usage? (for example: 'We have no current plans to add additional coal powered electricity generation')
Sign up for free to unlockIs executive remuneration linked to climate performance?
Sign up for free to unlockDoes the Board describe its role in the oversight of climate-related risks and opportunities?
Sign up for free to unlockDoes Design Therapeutics Inc disclose current and / or historical scope 2 emissions?
Sign up for free to unlockDoes Design Therapeutics Inc disclose water use targets?
Sign up for free to unlockDoes Design Therapeutics Inc have careers partnerships with academic institutions?
Sign up for free to unlockDid Design Therapeutics Inc have a product recall in the last two years?
Sign up for free to unlockDoes Design Therapeutics Inc disclose incidents of discrimination?
Sign up for free to unlockDoes Design Therapeutics Inc allow for Work Councils/Collective Agreements to be formed?
Sign up for free to unlockHas Design Therapeutics Inc issued a profit warning in the past 24 months?
Sign up for free to unlockDoes Design Therapeutics Inc disclose parental leave metrics?
Sign up for free to unlockDoes Design Therapeutics Inc disclose climate scenario or pathway analysis?
Sign up for free to unlockDoes Design Therapeutics Inc disclose current and / or historical scope 1 emissions?
Sign up for free to unlockAre Operating Expesnses linked to emissions reduction?
Sign up for free to unlockDoes Design Therapeutics Inc disclose the pay ratio of women to men?
Sign up for free to unlockDoes Design Therapeutics Inc support suppliers with sustainability related research and development?
Sign up for free to unlockDoes Design Therapeutics Inc disclose the number of operations that have been subject to human rights reviews or human rights impact assessments?
Sign up for free to unlockDoes Design Therapeutics Inc reflect climate-related risks in its financial statements?
Sign up for free to unlockIs there a statment that there is no plan to expand their carbon intensite energy assets? (for example: 'We have no current plans to carry out further drilling for oil,')
Sign up for free to unlockIs Design Therapeutics Inc involved in embryonic stem cell research?
Sign up for free to unlockDoes Design Therapeutics Inc disclose GHG and Air Emissions intensity?
Sign up for free to unlockDoes Design Therapeutics Inc disclose its waste policy?
Sign up for free to unlockDoes Design Therapeutics Inc report according to TCFD requirements?
Sign up for free to unlockDoes Design Therapeutics Inc disclose its policies for bribery, corruption, whistle-blower, conflict of interest?
Sign up for free to unlockDoes Design Therapeutics Inc disclose energy use targets?
Sign up for free to unlockDoes Design Therapeutics Inc disclose its Renewable Energy targets?
Subscription requiredAre emissions metrics verified by STBi?
Subscription requiredDoes Design Therapeutics Inc have a policy relating to cyber security?
Sign up for free to unlockHave a different question?
Potential Risks for Design Therapeutics Inc
These potential risks are based on the size, segment and geographies of the company.
Design Therapeutics, Inc. a preclinical-stage biopharmaceutical company, engages in the development of therapies for the treatment of genetic diseases caused by nucleotide repeat expansions. The company's portfolio of products comprises Friedreich Ataxia, a monogenic, autosomal recessive, progressive multi-system disease that affects organ systems dependent on mitochondrial function, eventually leading to neurological, cardiac, and metabolic dysfunction; and Myotonic Dystrophy Type-1 (DM1), a dominantly-inherited, monogenic progressive neuromuscular disease affecting skeletal muscle, heart, brain, and other organs. It is also developing GeneTAC product candidate portfolio for the treatment of other nucleotide repeat expansion-driven monogenic diseases, such as Fragile X syndrome, spinocerebellar ataxias, amyotrophic lateral sclerosis, frontotemporal dementia, Huntington disease, and spinobulbar muscular atrophy. Design Therapeutics, Inc. was incorporated in 2017 and is headquartered in Carlsbad, California.